Characterization of monoclonal antibody recognizing ERCC1 overexpression, a potential biomarker for cisplatin response

被引：0
|
作者：
Oishi, Takayuki [1 ]
Sasaki, Yuka [2 ]
Tong, Ying
Chen Lichao
Onodera, Takae [2 ]
Iwasa, Satoru
Udo, Emiko
Furusato, Bungo
Nakao, Kazuhiko
Yamada, Yasuhide
Hiraoka, Nobuyoshi
Masutani, Mitsuko [2 ]
机构：
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Genom Biomed, Nagasaki, Japan
[2] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol & Genom BioMed, Nagasaki, Japan
来源：
CANCER SCIENCE | 2021年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PJ17-2-3
引用
收藏
页码：915 / 915
页数：1
相关论文
共 50 条
  • [31] ROLE OF ERCC1 PROMOTER HYPERMETHYLATION IN DRUG RESISTANCE TO CISPLATIN IN HUMAN GLIOMAS
    Chen, H.
    Kwan, A.
    Chen, Z.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1147 - 1147
  • [32] ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas
    Laufs, Valeria
    Altieri, Barbara
    Sbiera, Silviu
    Kircher, Stefan
    Steinhauer, Sonja
    Beuschlein, Felix
    Quinkler, Marcus
    Willenberg, Holger S.
    Rosenwald, Andreas
    Fassnacht, Martin
    Ronchi, Cristina L.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2018, 178 (02) : 181 - 188
  • [33] Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer
    Heyza, Joshua R.
    Lei, Wen
    Watza, Donovan
    Zhang, Hao
    Chen, Wei
    Back, Jessica B.
    Schwartz, Ann G.
    Bepler, Gerold
    Patrick, Steve M.
    CLINICAL CANCER RESEARCH, 2019, 25 (08) : 2523 - 2536
  • [34] ERCC1 OVEREXPRESSION PREDICTS POOR PROGNOSIS IN PATIENTS WITH GASTRIC/GE JUNCTION ADENOCARCINOMA TREATED WITH ADJUVANT CISPLATIN-BASED CHEMOTHERAPY
    De Dosso, Sara
    Nucifora, Martina
    Zanellato, Elena
    Boldorini, Renzo
    Angelica, Sonzogni
    Fazio, Nicola
    Biffi, Roberto
    Bucci, Eraldo
    Luca, Mazzucchelli
    Frattini, Milo
    Saletti, Piercarlo
    ANNALS OF ONCOLOGY, 2012, 23 : 49 - 50
  • [35] Evaluation of inducible expression of ERCC1 as a biomarker of drug response in human colorectal cancer cell lines.
    Mallick, A. Basu
    Seetharam, R.
    Sood, A.
    Mariadason, J.
    Goel, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody
    David Hersi Smith
    Anne-Marie Kanstrup Fiehn
    Louise Fogh
    Ib Jarle Christensen
    Tine Plato Hansen
    Jan Stenvang
    Hans Jørgen Nielsen
    Kirsten Vang Nielsen
    Jane Preuss Hasselby
    Nils Brünner
    Sussie Steen Jensen
    Scientific Reports, 4
  • [37] Association of Polymorphisms and Expression of ERCC1 and XPA with the Response of Patients with Testicular Germ Cell Tumors treated with Cisplatin.
    Mendoza, J. R.
    Hernandez Hernandez, C. A.
    Fabian, E.
    Perez Montiel, M. D.
    Castro, C.
    Diaz, J. D.
    Gonzalez-Barrios, R.
    Martinez, J.
    Jimenez, M. A.
    Herrera, L. A.
    MOLECULAR BIOLOGY OF THE CELL, 2011, 22
  • [38] Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients
    Tejasvi, M. L. Avinash
    Maragathavalli, G.
    Putcha, Uday Kumar
    Ramakrishna, M.
    Vijayaraghavan, R.
    Avinash, Anulekha C. K.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2020, 63 (04) : 538 - 543
  • [39] ERCC1 Expression and Outcomes in Head and Neck Cancer Treated with Concurrent Cisplatin and Radiation
    Hayes, Mose
    Lan, Cynthia
    Yan, Jingsheng
    Xie, Yang
    Gray, Toby
    Amirkhan, Robin H.
    Dowell, Jonathan E.
    ANTICANCER RESEARCH, 2011, 31 (12) : 4135 - 4139
  • [40] PHARMACOGENOMICS LINK RS11615 OF ERCC1 TO CISPLATIN-INDUCED OTOTOXICITY
    Zehnhoff-Dinnesen, A. Am
    Deuster, D.
    Malath, I.
    Eveslage, M.
    Ciarimboli, G.
    Langer, T.
    Zolk, O.
    Juergens, H.
    Lanvers-Kaminsky, C.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 164 - 164
12345